Dupilumab, a Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature

Kim Blakely, BSc, PhD; Melinda Gooderham, MD, MSc, FRCPC; Kim Papp, MD, PhD, FRCPC


Skin Therapy Letter. 2016;21(2) 

In This Article


Over the last several years, a number of important scienti c and clinical discoveries have been made regarding the pathogenesis of AD. We now understand better than ever that AD results from defects in skin barrier function and innate and adaptive immune responses, both of which have important therapeutic implications. These discoveries not only explain the limitations of currently used treatments for AD, but also provide a map forward in our discovery of novel therapeutics for this dif cult-to-treat skin disorder. Dupilumab is helping to shed new light on the pathomechanisms driving atopic dermatitis, and leading the way towards highly effective control of this debilitating disease.